Ingrid Desar1, Carla M.L. van Herpen1,
J. J.A. van Asten2, W. Fiedler3, A.S. Govaerts4,
J. N.H. Timmer-Bonte1, E. G.W. ter Voert2, Antonio
Lambiase5, C. Bordignon5, A. Heerschap2, H.
W.M. van Laarhoven1
1Medical Oncology, Radboud University
Nijmegen Medical Center, Nijmegen, Netherlands; 2Radiology,
Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3Universitts-Krankenhaus
Hamburg-Eppendorf, Hamburg, Germany; 4EORTC Headquarters,
Brussels, Belgium; 5Molmed, Milan, Italy
Vascular
targeted TNF, NGR-hTNF, has antivascular properties. In a recent phase I
study, it was not possible to select an optimal biological dose of NGR-hTNF
from DCE-MRI measurements.(1) This study aims to examine the reasons for
this. Our results suggests that this was caused by a combination of the
following factors: (i) less adequate reproducibility in healthy liver tissue
due to more than expected heterogeneity in vascular response, (ii) more than
expected changes in healthy liver tissue which influences the amount of
contrast between metastases and healthyliver tissue (iii) difference in the
effect of NGR-hTNF between tumors related to tumor size and (iv) the
development of soluble TNF receptors.
Keywords